Genmab signs antibody research deal with Janssen Biotech
COPENHAGEN (Reuters) - Danish biopharma firm Genmab has agreed to collaborate with Janssen Biotech to create and develop antibodies using its DuoBody technology platform and will receive an upfront payment of $3.5 million, Genmab said.
Under the terms of the deal, Janssen will fully fund the research to be done at Genmab, and Genmab will potentially be entitled to milestone and license payments of up to about $175 million for each product as well as royalties on any commercialized products, Genmab said late on Thursday.
The deal with Janssen followed a collaboration agreement with Novartis in June to use Genmab's DuoBody technology.
The DuoBody platform, introduced in 2010 is a technology for the discovery and development of antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease, Genmab said in the statement.
(Reporting by John Acher; Editing by Eric Meijer)
- Tesla prevails in top Massachusetts court over direct sales
- Obama to deploy 3,000 troops as Eboola crisis worsens
- World stocks hit one-month low, caution ahead of Fed
- Russia needs government investment to avoid recession, says former finance minister
- Ahead of independence vote, Britain pledges state funding to Scotland